Eisai Announces Agreement with Pfizer on Strategic Alliance for Alzheimer's Disease Treatment Aricept®
PRNewswire
WOODCLIFF LAKE, N.J.

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") announced that it has reached a comprehensive agreement with Pfizer Inc. (Headquarters: New York, CEO and Chairman of the Board: Jeffrey Kindler, "Pfizer") regarding the strategic alliance for the Alzheimer's Disease treatment, Aricept (donepezil hydrochloride). Eisai and Pfizer have been in discussions to resolve their dispute concerning the strategic alliance and development agreement which was signed in October 1994.

  Main items which both parties agreed upon are as follows:


  --  A partial alteration of the Agreement for Aricept

Under this redefined alliance, Eisai and Pfizer will continue to co-promote Aricept in the U.S., Japan and key markets in Europe. The expiry of the Agreement for the co-promotion of Aricept in Japan will cease as of 31st of December, 2012.

-- New partnership in connection with a new product developed by Pfizer

Eisai will co-promote pregabalin in Japan, a treatment for neuropathic pain developed by Pfizer. Pfizer launched pregabalin in the U.S. and Europe with the brand name Lyrica and has filed a New Drug Application (NDA) in Japan.

Eisai expects this new collaboration with Pfizer to have a positive impact on its revenue and earnings after fiscal year 2010.

Eisai will continue its hhc mission to address unmet medical needs and make contributions to improving the quality of life of patients, their families and caregivers.

First Call Analyst:
FCMN Contact:

SOURCE: Eisai Co., Ltd.

CONTACT: Corporate Communications, Eisai Inc., +1-201-937-2591 or
+1-201-543-3892

Type Press Release

Date Released September 24, 2009

Tags:

RECENT RELEASES
Mar 5, 2024

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC...

Feb 28, 2024

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta...

Jan 18, 2024

Data from the Pivotal Phase 3 CLEAR Trial and Phase 2 KEYNOTE-B61 Trial Provide Further Insight into the Role of Lenvatinib Plus Pembrolizumab as a First-Line Treatment Option for Patients with...

Alerts - Release page
SUBSCRIBE TO OUR NEWS
* Required Fields